AN ASSOCIATION OF METABOLIC SYNDROME WITH NONALCOHOLIC FATTY LIVER DISEASE

Authors

  • SHWETA JAIN Department of Biochemistry, RK Medical College, Bhopal, Madhya Pradesh, India.
  • BISWAS SS Department of Biochemistry, RK Medical College, Bhopal, Madhya Pradesh, India.
  • SWATI JAIN Department of Community Medicine, RKDF Medical College, Bhopal, Madhya Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2024.v17i5.50946

Keywords:

Nonalcoholic fatty liver disease, Metabolic syndrome, Body mass index

Abstract

Objectives: Nonalcoholic fatty liver disease is strongly linked with hepatic fatty infiltration and visceral adiposity, therefore, being a cause and a result of metabolic syndrome. The objective of the study is to find an association of metabolic syndrome (MetS) with nonalcoholic fatty liver disease (NAFLD).

Methods: A total of 342 subjects from which 86 NAFLD 86 control were suitably selected for study duration of 1 year. Diagnosis of nonalcoholic fatty liver disease was done by liver imaging and based on liver enzymes. MetS assessment was done by the national cholesterol education program adult treatment panel III (NCEP ATP III) criteria. Estimation of all biochemical and hematological parameters and liver enzymes was done following standard guidelines. Mean comparison of quantitative data in different groups was analyzed with one-way analysis of variance.

Results: There were significant high levels of body mass index, waist circumference, and lipid profiles in NAFLD patients in comparison to control population (p<0.001). According to the NCEP ATP III criteria, 59.3% of NAFLD were present with MetS where risk estimate was significant (odds ratio=2.15).

Conclusion: This study suggests that there is an increased in all the components of MetS and gross changes in biochemical markers in cases of NAFLD. Therefore, whenever MetS factors are met in the clinical checkups, patients must be diagnosed for NAFLD by imaging (fatty liver).

Downloads

Download data is not yet available.

References

Barale C, Russo I. Influence of cardiometabolic risk factors on platelet function. Int J Mol Sci. 2020;21(2):623. doi: 10.3390/ijms21020623, PMID 31963572

Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851-61. doi: 10.1016/S2468-1253(22)00165-0, PMID 35798021

Jackson SE, Llewellyn CH, Smith L. The obesity epidemic-nature via nurture: A narrative review of high-income countries. SAGE Open Med. 2020;8:2050312120918265. doi: 10.1177/2050312120918265, PMID 32435480

Choudhary NS, Duseja A. Screening of cardiovascular disease in nonalcoholic fatty liver disease: Whom and how? J Clin Exp Hepatol. 2019;9(4):506-14. doi: 10.1016/j.jceh.2019.02.005, PMID 31516267

van den Berg EH, Douwes RM, de Meijer VE, Schreuder TC, Blokzijl H. Liver transplantation for NASH cirrhosis is not performed at the expense of major post-operative morbidity. Dig Liver Dis. 2018;50(1):68-75. doi: 10.1016/j.dld.2017.08.022, PMID 28935188

Cleeman J, Grundy S, Becker D, Clark L. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP III). JAMA. 2001;285:2486-97.

Tse C, Lisanti N, Grubert Van Iderstine M, Uhanova J, Minuk G, Faisal N. Comparison of different definitions of metabolic syndrome and their associations with non-alcoholic fatty liver disease: A retrospective study. Can Liver J. 2023 Dec 20;6(4):395-406. doi: 10.3138/canlivj-2023-0006.eCollection

Lu S, Xie Q, Kuang M, Hu C, Li X, Yang H, et al. Lipid metabolism, BMI, and the risk of nonalcoholic fatty liver disease in the general population: Evidence from a mediation analysis. J Transl Med. 2023;21(1):192. doi: 10.1186/s12967-023-04047-0, PMID 36915168

Published

07-05-2024

How to Cite

JAIN, S., B. SS, and S. JAIN. “AN ASSOCIATION OF METABOLIC SYNDROME WITH NONALCOHOLIC FATTY LIVER DISEASE”. Asian Journal of Pharmaceutical and Clinical Research, vol. 17, no. 5, May 2024, pp. 179-80, doi:10.22159/ajpcr.2024.v17i5.50946.

Issue

Section

Original Article(s)